Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus tislelizumab for newly diagnosed elderly extranodal NK/T cell lymphoma
ChiCTR2100048494Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and tislelizumab in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
tucidinostattislelizumab
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR2100048494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048494.